摘要
目的探究将吉西他滨纳入结合化疗方案中,以进行复发非霍奇金淋巴瘤治疗的临床价值及意义。方法选取2016年12月—2017年12月该院进行结合化疗治疗的复发非霍奇金淋巴瘤的患者96例,其中以未将吉西他滨纳入化疗治疗的48例患者的研究结果作为参照组,另48例选择将吉西他滨纳入结合化疗治疗的结果作为探究组,对比临床成效。结果结果显示,探究组总体有效、完全缓解、部分缓解分别为33例(68.75%)、4例(8.33%)、29例(60.42%),参照组为30例(62.50%),4例(8.33%)、26例(54.17%),可见,探究组患者治疗总体有效率、完全缓解率、部分缓解率等都与参照组相比,差异无统计学意义(χ~2=0.288、1.545、2.037;P=1.539,0.244,0.097>0.05);探究组肝肾损害、白细胞减低、血小板减少、恶心呕吐分别为:2例(4.17%)、16例(33.33%)、14例(29.17%)、27例(56.25%),均显著低于参照组(χ~2=5.674,10.422,8.546,7.018;P=0.004 9,0.003 5,0.002 4,0.001 6<0.05);两组生存情况差异无统计学意义(P>0.05)。结论对于复发非霍奇金淋巴瘤的患者,选择将吉西他滨加入结合化疗方案中,在取得与传统化疗药物相同的治疗效果前提下,能够减少化疗药物使用对人体的不良影响,建议临床广泛应用于复发非霍奇金淋巴瘤的治疗中。
Objective To study the clinical value and significance of gemcitabine combined with chemotherapy plan in treatment of recurrent non-Hodgkin＇s lymphoma. Methods 96 cases of patients with recurrent non-Hodgkin＇s lymphoma treated in our hospital from December 2016 to December 2017 were selected, and divided into two groups, with48 cases in each, the control group were treated with gemcitabine combined with chemotherapy, while the study group were treated with chemotherapy, and the clinical effect was compared between the two groups. Results The results showed that 33 cases were effective（68.75%）, 4 cases were totally relieved（8.33%）, 29 cases were partially relieved（60.42%）, in the study group, and in the control group, 30 cases were effective（62.50%）, 4 cases were totally relieved（8.33%） and 26 cases were partially relieved（54.17%）, and the differences in the total effective rate, total relief rate and partial relief rate between the two groups were not obvious, the difference was not statistically significant（χ^2=0.288,1.545,2.037;P=1.539,0.244,0.097 〉0.05）; and the liver and kidney damage, leucopenia, thrombopenia and nausea and vomiting were respectively 2 cases（ 4.17%）, 16 cases（33.33%）, 14 cases（29.17%）, 27 cases（56.25%）, which were obviously lower than those in the control group（χ^2=5.674,10.422,8.546,7.018; P=0.004 9, 0.003 5, 0.002 4, 0.001 6〈0.05）, and the differences between groups were not obvious（P〉0.05）. Conclusion The effect of gemcitabine combined with chemotherapy in patients with recurrent non-Hodgkin＇s lymphoma can reduce the adverse effect on the human body on the premise of obtaining the same treatment effect as the traditional chemotherapy drugs, and it is suggested to be widely used in the treatment of recurrent non-Hodgkin＇s lymphoma.
作者
杜立华
DU Li-hua(Department of Hematology,Liaohe Oil General Hospital,Panjin,Liaoning Province,124100 China)
出处
《系统医学》
2018年第13期129-132,共4页
Systems Medicine
关键词
复发非霍奇金淋巴瘤
结合化疗方案
吉西他滨
临床分析
Recurrent non-Hodgkin＇s lymphoma
Combined with chemotherapy plan
Gemeitabine
Clinical analysis
